175 related articles for article (PubMed ID: 38414025)
1. DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target.
Chen M; Zhang S; Wang F; He J; Jiang W; Zhang L
J Transl Med; 2024 Feb; 22(1):209. PubMed ID: 38414025
[TBL] [Abstract][Full Text] [Related]
2. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
3. Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma.
Chen R; Wang Z; Lu T; Liu Y; Ji Y; Yu Y; Tou F; Guo S
Thorac Cancer; 2023 Apr; 14(10):893-912. PubMed ID: 36825773
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
5. Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma.
Jiang W; Wei Q; Xie H; Wu D; He H; Lv X
Anal Cell Pathol (Amst); 2023; 2023():4522045. PubMed ID: 37416927
[TBL] [Abstract][Full Text] [Related]
6. Integrated bioinformatics analysis reveals CDK1 and PLK1 as potential therapeutic targets of lung adenocarcinoma.
Li S; Li H; Cao Y; Geng H; Ren F; Li K; Dai C; Li N
Medicine (Baltimore); 2021 Aug; 100(32):e26474. PubMed ID: 34397869
[TBL] [Abstract][Full Text] [Related]
7. Tectoridin and PLK1 inhibitor synergistically promote the apoptosis of lung adenocarcinoma cells: Bioinformatic analysis of TCGA and TCMSP.
Wang M; Zhao F; Li Z; Li X; Dong L
Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2417-2426. PubMed ID: 37014402
[TBL] [Abstract][Full Text] [Related]
8. Exploring the mechanism of 6-Methoxydihydrosanguinarine in the treatment of lung adenocarcinoma based on network pharmacology, molecular docking and experimental investigation.
Liu X; Ren Y; Qin S; Yang Z
BMC Complement Med Ther; 2024 May; 24(1):202. PubMed ID: 38783288
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer landscape of CENPO and its underlying mechanism in LUAD.
Shi T; Hu Z; Tian L; Yang Y
Respir Res; 2023 Apr; 24(1):113. PubMed ID: 37061713
[TBL] [Abstract][Full Text] [Related]
10. PLK1 Is a Potential Prognostic Factor Associated with the Tumor Microenvironment in Lung Adenocarcinoma.
Wang L; Gao M; Sun D; Wu H; Lv S; Li Y; Li L
Biomed Res Int; 2022; 2022():7848771. PubMed ID: 35941968
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of BCCIP predicts an unfavorable prognosis and promotes the proliferation and migration of lung adenocarcinoma.
Shi J; Lv X; Li W; Ming Z; Zeng L; Yuan J; Chen Y; Liu B; Yang S
Thorac Cancer; 2021 Sep; 12(17):2324-2338. PubMed ID: 34297484
[TBL] [Abstract][Full Text] [Related]
12. Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma.
Feng W; He Z; Shi L; Zhu Z; Ma H
Biochem Genet; 2023 Oct; 61(5):1937-1966. PubMed ID: 36892747
[TBL] [Abstract][Full Text] [Related]
13. NPM3 as a novel oncogenic factor and poor prognostic marker contributes to cell proliferation and migration in lung adenocarcinoma.
Wei S; Xing J; Lu K; Wang K; Yu W
Hereditas; 2023 May; 160(1):27. PubMed ID: 37254219
[TBL] [Abstract][Full Text] [Related]
14. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
PeerJ; 2023; 11():e16166. PubMed ID: 37790630
[TBL] [Abstract][Full Text] [Related]
15. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
Fan K; Zhang BH; Han D; Sun YC
BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-147b promotes lung adenocarcinoma cell aggressiveness through negatively regulating microfibril-associated glycoprotein 4 (MFAP4) and affects prognosis of lung adenocarcinoma patients.
Feng YY; Liu CH; Xue Y; Chen YY; Wang YL; Wu XZ
Gene; 2020 Mar; 730():144316. PubMed ID: 31884109
[TBL] [Abstract][Full Text] [Related]
17. Tanshinone IIA suppresses the progression of lung adenocarcinoma through regulating CCNA2-CDK2 complex and AURKA/PLK1 pathway.
Li Z; Zhang Y; Zhou Y; Wang F; Yin C; Ding L; Zhang S
Sci Rep; 2021 Dec; 11(1):23681. PubMed ID: 34880385
[TBL] [Abstract][Full Text] [Related]
18. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
Liang H; Li Y; Qu Y; Zhang L
Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
[TBL] [Abstract][Full Text] [Related]
19. SERPINB5 is a prognostic biomarker and promotes proliferation, metastasis and epithelial-mesenchymal transition (EMT) in lung adenocarcinoma.
He X; Ma Y; Huang Z; Wang G; Wang W; Zhang R; Guo G; Zhang X; Wen Y; Zhang L
Thorac Cancer; 2023 Aug; 14(23):2275-2287. PubMed ID: 37424293
[TBL] [Abstract][Full Text] [Related]
20. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
